Hydroxychloroquine Dosage in Photosensitive Dermatoses
For photosensitive dermatoses, hydroxychloroquine should be dosed at ≤5.0 mg/kg based on actual body weight per day, typically translating to 200 mg twice daily (400 mg/day total) for most adults, with a maximum of 400 mg/day even in severely obese patients. This dosing minimizes retinal toxicity risk while maintaining therapeutic efficacy for photoprotection 1, 2.
Dosing Algorithm
Calculate the dose using actual body weight:
- Target: ≤5.0 mg/kg/day of actual body weight
- For a 70 kg patient: maximum 350 mg/day (typically prescribed as 200 mg twice daily = 400 mg/day is acceptable)
- Critical ceiling: Never exceed 400 mg/day regardless of body weight 2, 3
- For thin patients: Use actual weight, not ideal weight, as ideal weight calculations lead to overdosing 1
Special populations requiring dose adjustment:
- Renal disease: Reduce dose by 50% if GFR <30 mL/min, as hydroxychloroquine is renally cleared and accumulation dramatically increases toxicity risk 4, 2
- Elderly patients: No specific age-based reduction needed, but calculate carefully based on actual weight 1
- Severely obese patients: Cap at 400 mg/day maximum 3
Rationale for This Dosing
The 5.0 mg/kg threshold is based on large-scale data showing that patients maintaining this dose have <1% risk of retinopathy in the first 5 years and <2% risk up to 10 years 1. Risk escalates sharply to ~20% after 20 years, but annual incremental risk remains <4% even at 20 years when the 5.0 mg/kg limit is respected 1.
Higher doses (>5.0 mg/kg) dramatically increase toxicity risk—patients receiving 8 mg/kg showed 25-40% incidence of retinopathy within just 1-2 years 1. The evidence is unequivocal: daily dose relative to body weight is the single most critical determinant of retinal toxicity risk 1.
Critical Monitoring Requirements
Baseline ophthalmologic examination before starting therapy to document normal retinal structure and rule out pre-existing macular disease 1, 3. This should include:
- Fundus examination
- Optical coherence tomography (OCT)
- Fundus autofluorescence (FAF)
Annual screening should begin after 5 years of use (or sooner if major risk factors present) 1, 2, 3. Primary screening tools are OCT and wide-pattern FAF, with visual fields as confirmatory testing 3.
Important Caveats for Photosensitive Dermatoses
Paradoxical photosensitivity: While hydroxychloroquine is photoprotective for most conditions, rare cases of hydroxychloroquine-induced photodermatosis have been reported 5, 6, 7, 8. If a patient develops worsening photosensitivity 6 days to 10 weeks after starting hydroxychloroquine, consider drug-induced photodermatosis and discontinue the medication 5.
Porphyria cutanea tarda exception: For this specific photosensitive condition, use a much lower dose of 125 mg twice weekly (not daily), as standard lupus doses (400 mg/day) can cause severe hepatotoxicity 9, 10. This is a critical distinction—the question asks about photosensitive dermatoses broadly, but if the specific diagnosis is porphyria cutanea tarda, the dosing paradigm is completely different.
Duration and Discontinuation
For photosensitive dermatoses like lupus erythematosus, hydroxychloroquine should be continued indefinitely as it reduces disease flares and provides ongoing photoprotection 4, 11. The drug has a half-life of 40-50 days with chronic use, so benefits persist for months after discontinuation, but so does toxicity risk if retinopathy has developed 12.
Retinopathy is irreversible and may progress even after stopping the drug, particularly if severe damage has occurred before detection 1. Early-detected mild retinopathy shows minimal progression after discontinuation, emphasizing the critical importance of adhering to proper dosing and screening protocols 1, 3.